BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lantus (insulin glargine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lantus (insulin glargine)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03463564-315@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lantus (insulin glargine): Phase 4 readout est. (NCT03463564)
DESCRIPTION:Lantus (insulin glargine)\, phase 4\, Type 1 Diabetes.\nStudy: 
 Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic C
 ontrol in Type 1 Diabetic Patients\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/insulin-glargi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3463564
URL:https://assetmemo.bio/drug/insulin-glargine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07173712-315@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lantus (insulin glargine): Phase 4 readout est. (NCT07173712)
DESCRIPTION:Lantus (insulin glargine)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Di
 abetes\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/insulin-glargine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07173712
URL:https://assetmemo.bio/drug/insulin-glargine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307235-315@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lantus (insulin glargine): Phase 4 readout est. (NCT07307235)
DESCRIPTION:Lantus (insulin glargine)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world A
 dult China Population With Uncontrolled Type 2 Diabetes on Oral Agents\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/insulin-glargine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07307235
URL:https://assetmemo.bio/drug/insulin-glargine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224893-315@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Lantus (insulin glargine): Phase 4 readout est. (NCT07224893)
DESCRIPTION:Lantus (insulin glargine)\, phase 4.\nStudy: Once-Daily vs Twic
 e-Daily Insulin Glargine in Pregestational Diabetes Management\nEstimated 
 primary completion: 1 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/insulin-glargine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07224893
URL:https://assetmemo.bio/drug/insulin-glargine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07117240-315@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Lantus (insulin glargine): Phase 4 readout est. (NCT07117240)
DESCRIPTION:Lantus (insulin glargine)\, phase 4.\nStudy: Evaluation of the 
 Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced D
 iabetes\nEstimated primary completion: 9 February 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/insulin-glargine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07117240
URL:https://assetmemo.bio/drug/insulin-glargine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07568574-315@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Lantus (insulin glargine): Phase na readout est. (NCT07568574)
DESCRIPTION:Lantus (insulin glargine)\, phase na.\nStudy: Impact of Medical
 ly Supervised Performance-Enhancing Substances (PES) on Elite Athletes\nEs
 timated primary completion: 1 May 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/insulin-glargine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07568574
URL:https://assetmemo.bio/drug/insulin-glargine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445946-315@assetmemo.bio
DTSTAMP:20261121T004949Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lantus (insulin glargine): Phase 4 readout est. (NCT06445946)
DESCRIPTION:Lantus (insulin glargine)\, phase 4.\nStudy: DECIDE: A Comparat
 ive Effectiveness Trial of Metformin Versus Insulin for the Treatment of G
 estational Diabetes\nEstimated primary completion: December 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/insulin-glargine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06445946
URL:https://assetmemo.bio/drug/insulin-glargine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
